Niagen Bioscience, Inc. (NAGE)vsBeiGene, Ltd. (ONC)
NAGE
Niagen Bioscience, Inc.
$4.52
-0.44%
HEALTHCARE · Cap: $361.96M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 4028% more annual revenue ($5.34B vs $129.42M). NAGE leads profitability with a 13.4% profit margin vs 5.4%. NAGE trades at a lower P/E of 22.6x. NAGE earns a higher WallStSmart Score of 45/100 (D).
NAGE
Hold45
out of 100
Grade: D
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-275.7%
Fair Value
$1.36
Current Price
$4.52
$3.16 premium
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 28 in profit
16.2% revenue growth
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
Earnings declined 41.6%
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NAGE
The strongest argument for NAGE centers on Return on Equity, Revenue Growth. Revenue growth of 16.2% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : NAGE
The primary concerns for NAGE are Market Cap, EPS Growth.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
NAGE profiles as a growth stock while ONC is a hypergrowth play — different risk/reward profiles.
NAGE carries more volatility with a beta of 2.23 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
NAGE scores higher overall (45/100 vs 42/100) and 16.2% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Niagen Bioscience, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Niagen Bioscience, Inc. is a bioscience company engages in developing healthy aging products. The company is headquartered in Los Angeles, California.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?